Beyond QSIT

Noferi,Joseph;Worden,Daniel;

Publication

Article

April 15, 2002

BioPharm International

BioPharm International-04-01-2002

Volume15

Issue 4

Beyond QSIT

Author(s):

Joseph F. Noferi, Esq.,Daniel E. Worden

by Joseph F. Noferi, Pharmacia GS API Biopharma and Daniel E. Worden If a process is out of control, an FDA inspector will find it, eventually. Companies that emerge as winners will be those that embrace compliance as a core business practice. Systems models provide strategic competitive advantage.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Analytical Advances: Paperless or Less Paper?

Outsourcing Outlook: Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives

Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning

Beyond QSIT

Determining Protein Concentration, Part 1: Methodology

Guest Editorial: The Protein Production Challenge

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!